Grant winners - 23 May 2013

May 23, 2013

Action Medical Research

Research Project Grants

  • Award winner: Peter Taylor
  • Institution: University College London
  • Value: £114,845

Bacterial meningitis in newborn babies: harnessing the body’s natural defences


Leverhulme Trust

Research Leadership Awards

Multiphysics modelling of solar energy harvesting in biomimetic photovoltaics

Singular stochastic partial differential equations

Form and function in a microbial world

Priming plant defence: from its onset to transgenerational maintenance

Major Research Fellowships

Chance and containment: state lotteries in Britain and Europe c.1600- 1850

Useful books: reading and talking in the English Renaissance

The English parish, c.1290-c.1535

Race, nation and genomics: biology and society


Royal Society

Wolfson Research Merit Awards
Awards are worth £10,000-£30,000 a year, which is a salary enhancement

An exploration of the strong interaction under extreme conditions

Nanoscale multiferroic materials and heterostructures for oxide electronics


In detail

National Institute for Health Research

Award winner: Tim Maughan
Institution: University of Oxford
Value: £3,525,623

Molecular selection of therapy in metastatic colorectal cancer: a molecularly stratified randomised controlled trial programme (FOCUS 4)

Tests that can be done on tumour samples from patients with advanced bowel cancer may help to select the best treatment options for an individual patient. There are a number of new cancer drugs that are more likely to be helpful in one subtype of bowel cancer than in another. The FOCUS 4 trial aims to recruit more than 1,500 patients across the UK to evaluate how well these new drugs work. Patients diagnosed with bowel cancer that is inoperable or has spread into other areas of the body will be invited to join this trial. Those who join will start on a course of chemotherapy for up to 16 weeks. In this time, a piece of the patient’s tumour will be analysed using two sorts of tests to find out more about its molecular make-up. The results will place the individual into subtypes of colorectal cancer. Patients will be assessed during and after the 16 weeks of chemotherapy to see how the tumour is responding to standard treatment.

Register to continue

Why register?

  • Registration is free and only takes a moment
  • Once registered, you can read 3 articles a month
  • Sign up for our newsletter
Please Login or Register to read this article.